Development of a predictive model for meglumine antimoniate treatment failure in patients with cutaneous leishmaniasis: Aretrospective cohort study
{{output}}
Background: Although alternative therapies for cutaneous leishmaniasis (CL) are available, systemic meglumine antimoniate (MA) remains the first-line treatment in many endemic regions. Its use is nevertheless associated with seri... ...
